Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.69 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | F9 | P00740 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14262212 | 0.95 | F10 (0.68) | F10F2F9PRSS1PRSS2 | |
| SCHEMBL1253895 | 0.95 | F10 (0.68) | F10F2F9PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL3339445 | 0.94 | F10 (0.67) | F10F2F9PRSS1PRSS2 | |
| SCHEMBL1322304 | 0.94 | F10 (0.71) | F10F2 | |
| Hydrochloric Acid SCHEMBL1504019 | 0.94 | F10 (0.70) | F10F2 | |
| SCHEMBL1503685 | 0.91 | F10 (0.62) | F10F2 | |
| SCHEMBL1503832 | 0.90 | F10 (0.66) | F10F2F9PRSS1PRSS2 | |
| SCHEMBL1503718 | 0.90 | F10 (0.61) | F10F2F9PRSS1PRSS2 | |
| SCHEMBL1503753 | 0.87 | F10 (0.63) | F10F2 | |
| SCHEMBL1503800 | 0.87 | F10 (0.65) | F10F2F9PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | F10 4/4885F2 1/4885F9 20/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | F10 152/4885F2 1/4885F9 100/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | F10 9/4885F2 1/4885F9 41/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F9 753/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | F10 196/4885F2 4/4885F9 753/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F9 753/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | F10 72/4885F2 4/4885F9 562/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | F10 127/4885F2 3/4885F9 507/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F9 753/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | F10 4/4885F2 1/4885F9 20/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | F10 138/4885F2 4/4885F9 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.